Related Experiment Videos
The action of interferon alpha on human carcinoid tumours
1Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Abstract:
The action of IFN-alpha has been studied in patients with carcinoid tumours. More than 300 patients have been treated with IFN-alpha for long periods of time (median 2.5 years). IFN-alpha exerts many pleiotrophic effects in carcinoid tumours. Antiproliferative effects are manifest mainly by a cell cycle block in GO-G1 phase and prolongation of the S-phase. Hormone synthesis is impaired with reduced circulating hormone levels after IFN-alpha therapy and the mechanism includes reduction of mRNA expression for various hormones. Induction in vitro of the nuclear enzyme 2'-5-A synthetase in tumour cells correlates with biochemical response and might account for reduced mRNA expression. IFN-alpha induces significantly increased intratumoral fibrosis in carcinoid metastases without significant changes in tumour size. Finally IFN-alpha causes alteration of the major histocompatibility complex (MHC) with increased expression of class I antigens on the tumour cells. The net result of all these effects of IFN-alpha is an antitumour effect in 70-80% of carcinoid tumour patients with biochemical control and abrogated tumour growth for extended periods of time. However, when IFN-alpha therapy is withdrawn tumour progression occurs within 3-9 months, indicating a controlling but not curing effect.
Insights
Interferon-alpha (IFN-alpha) demonstrates significant antitumor effects in carcinoid tumors by inhibiting proliferation and hormone synthesis. While effective for long-term tumor control, IFN-alpha therapy does not cure carcinoid tumors, as progression resumes upon discontinuation.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Carcinoid tumors are neuroendocrine neoplasms with diverse clinical manifestations.
- Interferon-alpha (IFN-alpha) has been explored as a therapeutic agent for carcinoid tumors.
- Understanding the mechanisms of IFN-alpha action is crucial for optimizing carcinoid tumor treatment.
Purpose of the Study:
- To investigate the multifaceted effects of IFN-alpha in patients with carcinoid tumors.
- To elucidate the antiproliferative and hormone-modulating mechanisms of IFN-alpha.
- To assess the long-term efficacy and limitations of IFN-alpha therapy in carcinoid tumor management.
Main Methods:
- Analysis of data from over 300 patients treated with IFN-alpha for extended periods.
- Evaluation of IFN-alpha's impact on tumor cell cycle, hormone synthesis, and mRNA expression.
- Assessment of intratumoral fibrosis, tumor size, and major histocompatibility complex (MHC) expression.
- Correlation of in vitro 2'-5-A synthetase induction with biochemical response.
Main Results:
- IFN-alpha induced antiproliferative effects via cell cycle arrest (G0-G1) and S-phase prolongation.
- Hormone synthesis was impaired, leading to reduced circulating hormone levels, linked to decreased mRNA expression.
- Increased intratumoral fibrosis was observed without significant changes in tumor size.
- Enhanced expression of MHC class I antigens on tumor cells was noted.
- Biochemical control and abrogated tumor growth were achieved in 70-80% of patients.
Conclusions:
- IFN-alpha exerts pleiotropic antitumor effects in carcinoid tumors, including antiproliferative and hormone-suppressive actions.
- The therapy leads to significant tumor control and biochemical stabilization for extended durations.
- IFN-alpha therapy controls but does not cure carcinoid tumors, with disease progression observed upon treatment cessation.